Morepen Laboratories Ltd Management Discussions

GLOBAL PHARMACEUTICAL SCENARIO

As of 2024, the global pharmaceutical industry was valued at approximately USD 1.64 trillion, reflecting a sustained upward trajectory over the past decade. From 2018 to 2024, the market expanded at a compound annual growth rate (CAGR) of around 4.8%, underpinned by a convergence of demographic, medical, and technological factors. Central to this growth was the rising burden of chronic non-communicable diseases, an ageing global population, and increased life expectancy. Pharmaceutical innovation also advanced rapidly, particularly in areas such as oncology, immunology, and rare diseases, while transformative technologies like cell and gene therapy, mRNA platforms, and artificial intelligence began reshaping both drug discovery and delivery. At the same time, digital health integration from wearable diagnostics to telemedicine enhanced patient engagement and created new models of personalized care. These drivers laid the groundwork for the industrys projected expansion to approximately USD 2.35 trillion by 2030, with future growth increasingly tied to emerging market expansion, innovation pipelines, and manufacturing decentralization.

New Therapeutic Growth Drivers

The therapeutic landscape is undergoing a decisive shift as innovation increasingly targets complex and high-burden disease categories. Oncology remains the single largest therapeutic area, valued at over USD 337 billion in 2024 and expected to grow at a CAGR of 5.5% to 6.2% through 2028. Growth in this area is being driven by advanced immunotherapies, antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell (CAR-T) treatments. In parallel, the diabetes and obesity segments are experiencing an inflexion point due to GLP-1 receptor agonists such as semaglutide and tirzepatide, which have demonstrated substantial efficacy in both weight reduction and glycemic control. These drugs are projected to form a therapeutic class exceeding USD 100 billion in value by 2030.

Neurology is also emerging as a strategic therapeutic priority, with significant investments being directed toward Alzheimers, Parkinsons disease, and rare central nervous system (CNS) disorders. Advancements in biomarker discovery, AI-assisted diagnostics, and gene therapies are expected to unlock new treatment pathways. Mental health is gaining renewed attention as well, especially in post-pandemic markets. Pharmaceutical pipelines now include a growing number of therapies targeting depression, anxiety, post-traumatic stress disorder (PTSD), and other psychiatric conditions, many of which are designed for integration with digital health platforms to improve adherence and outcomes.

The broader fields of cell and gene therapies are transitioning from experimental to commercial stages. Between 2025 and 2030, an estimated 25 new cell and gene therapy products are expected to receive regulatory approvals globally. However, scalability and affordability remain critical bottlenecks, necessitating innovation not just in bioprocessing but also in reimbursement models and regulatory harmonisation across major markets.

Technological and Structural Shifts

The next phase of pharmaceutical innovation will be shaped as much by technology and manufacturing transformation as by clinical breakthroughs. Artificial intelligence has become integral to the R&D process. By 2025, over 150 drug candidates in various stages of development will be either AI-generated or AI-optimised, contributing to time and cost reductions of up to 30% in early-phase research. Companion diagnostics, especially in oncology and rare diseases, are becoming routine, enabling personalised treatment plans and improving clinical efficacy rates.

Digital therapeutics (DTx) have moved from fringe innovation to a recognised part of the treatment ecosystem. In countries like Germany and select U.S. states, DTx solutions are now reimbursed under public or private insurance, particularly for conditions such as insomnia, ADHD, and chronic pain. These hybrid treatment models blending pharmaceutical interventions with algorithm-based digital tools are gaining traction across regulatory agencies and health systems.

From a structural standpoint, the pharmaceutical supply chain is being actively reconfigured in response to geopolitical tensions and post-pandemic disruptions. Regionalisation is gaining momentum, with the United States, European Union, and India all accelerating investments in domestic API and biosimilar production. The expansion of Indias Production Linked Incentive (PLI) scheme and similar reshoring incentives in the U.S. and Europe are designed to reduce reliance on single-country sourcing, particularly from China, and to enhance supply security for critical therapeutics. Together, these shifts are not only redefining cost structures and risk profiles but are also reinforcing sovereign control over pharmaceutical manufacturing capacities.

As the pharmaceutical industry transitions into 2025 and beyond, new structural shifts are emerging across the value chain, ranging from research and development to production and market access. One of the most critical transformations is the accelerated adoption of sustainability practices in pharmaceutical manufacturing. Global pressure to reduce environmental impact driven by government mandates, investor scrutiny, and evolving consumer expectations is forcing pharmaceutical companies to rethink their operational models. Green chemistry, carbon-neutral facilities, and sustainable packaging are no longer niche innovations but are becoming industry-wide standards. The European Unions Green Deal, Indias push for environmentally compliant production through its revised ESG norms, and similar regulatory initiatives in the United States and Japan are placing sustainability at the core of long-term competitiveness. Companies that proactively invest in cleaner processes, solvent recovery systems, and circular supply chains are expected to gain preferential access to markets and procurement contracts.

Another major development from 2025 onward is the evolution of global regulatory frameworks, which are increasingly converging across regions. Regulatory agencies such as the U.S. FDA, EMA (European Medicines Agency), and Japans PMDA are moving toward more collaborative, technology-enabled, and patient-centric review models. Fast-track approvals, adaptive clinical trial designs, and real-time data integration are becoming more commonplace, especially for breakthrough therapies and digital therapeutics. This global regulatory alignment is particularly significant for emerging technologies such as AI-designed molecules, RNA-based therapies, and connected drug-device combinations, where standardized pathways can shorten time-to-market and improve patient access. For Indian and Southeast Asian firms seeking entry into regulated markets, aligning with these evolving regulatory standards presents both a challenge and an opportunity for growth.

Finally, the contract development and manufacturing organisation (CDMO) segment is becoming a key pillar of global pharmaceutical growth. Rising drug complexity, coupled with the need for faster scalability and flexible capacity, is pushing global firms to increasingly rely on outsourcing, particularly for biologics, high-potency APIs (HPAPIs), and novel formulation technologies. India, South Korea, and Singapore are emerging as preferred CDMO hubs due to their technical capabilities, cost-efficiency, and improving regulatory compliance. From biosimilars to advanced injectable formats, the shift toward specialised CDMO partnerships is helping multinational companies reduce time-to-market while managing risks across fragmented supply chains. This trend also supports broader industry goals of agility and localisation, particularly as geopolitical uncertainty and pandemic-era lessons continue to shape future manufacturing strategies.

These developments rooted in sustainability, regulatory modernization, and supply chain transformation are redefining how pharmaceutical companies compete and create value. The winners of the next decade will not simply be those with breakthrough molecules, but those that align innovation with responsibility, agility, and global integration.

Geographical Markets

By the close of 2024, the global pharmaceutical market was still largely concentrated within a few dominant geographies, though emerging markets had begun to claim a growing share. North America continued to lead, accounting for approximately 42% of global pharmaceutical revenues. The United States remained the single largest pharmaceutical market in the world, backed by a mature insurance system, high healthcare expenditure, and deep-rooted innovation infrastructure. Over 50% of global drug development pipelines were concentrated in the U.S., with particular strength in biologics, immunotherapies, and breakthrough oncology treatments. Regulatory support mechanisms, such as the FDAs breakthrough therapy designation and the Orphan Drug Act, enabled faster approval timelines and commercial scalability, reinforcing the U.S.s leadership in therapeutic innovation. However, the region also faced increasing scrutiny over drug pricing, prompting ongoing policy debates around affordability and transparency.

Europe contributed roughly 23% of the total global pharmaceutical value by 2024. The continent remained an essential hub for biosimilar development, vaccine innovation, and therapeutic antibody production. Countries like Germany, France, Switzerland, and the United Kingdom played pivotal roles in manufacturing, while also maintaining robust clinical trial infrastructure. Nonetheless, Europes growth potential was constrained by a fragmented regulatory environment, pricing controls, and dependence on imported APIs, particularly from China and India. Still, efforts under the EUs Pharmaceutical Strategy aimed to strengthen regional resilience through enhanced manufacturing capacity, public-private R&D partnerships, and improved pandemic preparedness. Europe also made strides in advancing digital therapeutics and increasing access to biologics via aggressive biosimilar substitution policies.

The Asia-Pacific region emerged as the fastest-growing pharmaceutical geography, capturing nearly 20% of global market share by 2024. This growth, estimated at a CAGR of 7 8%, was led by China and India. China rapidly scaled its pharmaceutical output and innovation capabilities, driven by state-funded R&D, an evolving regulatory regime, and major investment in biotech clusters. Oncology, rare diseases, and biosimilars formed the backbone of Chinas therapeutic expansion. India, already established as the worlds largest supplier of generics and vaccines, continued to enhance its competitive edge in bulk drugs, complex APIs, injectables, and Contract Development and Manufacturing Organization (CDMO) services. In parallel, Japan and South Korea maintained a stronghold in precision diagnostics, robotic surgery technologies, and digital health integration, though their pharmaceutical sectors matured at a slower pace compared to their neighbours.

The rest of the world, comprising Latin America, Africa, and the Middle East, contributed approximately 15% of the remaining global market value in 2024. While these regions exhibited diverse growth profiles, several structural challenges persisted, including low public healthcare funding, weak infrastructure, and regulatory instability. Nevertheless, countries such as Brazil, Saudi Arabia, and South Africa led localized efforts to expand manufacturing capacity and improve access to essential medicines. In Africa, the pharmaceutical sector remained highly underpenetrated but critical, with growing demand for vaccines, anti-infectives, and maternal-child health interventions. Global institutions like the WHO and Gavi continued to support vaccine access and capacity-building initiatives, though funding gaps remained a significant barrier to scalable growth.

DOMESTIC PHARMACEUTICAL MARKET

Indias domestic pharmaceutical market has consistently proven to be one of the most resilient and dynamic components of the countrys economic framework. As of FY24, the Indian pharmaceutical sector was valued at approximately 521,000 crore, placing it among the top three globally in terms of production volume and the 14th in terms of value. Between FY18 and FY24, the domestic market expanded at a CAGR of 8.6%, supported by sustained demand across both chronic and acute therapy areas. Notably, chronic therapy segments such as anti-diabetics, cardiovascular drugs, and oncology treatments contributed significantly to this growth, with oncology registering some of the fastest expansion rates due to rising lifestyle diseases and improved diagnostic access.

A significant structural driver of this performance has been Indias demographic profile. With over 1.4 billion citizens, the country not only represents a vast base of pharmaceutical consumers but also a population undergoing a major epidemiological shift. Non-communicable diseases (NCDs) now account for over 65% of deaths in India. Lifestyle-related ailments, such as diabetes, hypertension, and respiratory disorders, have emerged as leading public health challenges. The rising middle class, greater life expectancy, and increased health awareness-especially in Tier 2 and Tier 3 cities-have further elevated medicine consumption. These trends created consistent volume growth across major therapy areas, with cardiovascular and anti-diabetic drugs witnessing over 10% annual growth by FY24.

Government intervention has also played a pivotal role in shaping the domestic landscape. Initiatives like the Pradhan Mantri Jan Aushadhi Yojana have expanded access to affordable generics, while the Ayushman Bharat Digital Mission (ABDM) has begun to lay the foundation for a connected, patient-centric health system. By 2024, more than 71 million Ayushman Bharat Health Account (ABHA) IDs had been issued, and millions of records had been digitally linked, marking a shift toward integrated, tech-enabled healthcare delivery. Additionally, the PLI Scheme for Pharmaceuticals and Medical Devices has been instrumental in reducing Indias over dependence on imports, especially for Active Pharmaceutical Ingredients (APIs). Targeted investments through the scheme are expected to generate over 20,000 direct jobs and mobilize 15,000 crore in private capital by 2026.

As India moves into 2025 and beyond, the pharmaceutical industry is expected to deepen its transformation from a generics-led model toward a more innovation-driven, tech-integrated ecosystem. The domestic market is projected to grow at a CAGR of 8.1%, reaching 709,000 crore by FY28. This expansion will not only be volume-led but will also reflect greater therapeutic complexity. For example, dermatology is expected to grow at a CAGR of 7.1%, while respiratory and cardiovascular therapies continue to maintain strong momentum. Oncology is projected to outpace most categories, driven by rising incidence, better access to early diagnosis, and the entry of targeted therapies and biosimilars.

Leading companies are ramping up investments in research and development, with a focus on new chemical entities (NCEs), complex generics, and biosimilars. Hyderabad, Bengaluru, and Ahmedabad are becoming R&D hubs, supported by global CRO partnerships and AI-driven clinical research tools. The number of Indian clinical trials approved for complex and targeted therapies is steadily rising, aligning with the global push for precision medicine.

A key trend shaping the domestic market is digital health adoption. With e-pharmacies now accounting for nearly 15 18% of the urban drug retail space and projected to grow at 21 34% CAGR through 2028, the model of healthcare delivery is rapidly evolving. Telemedicine, wearable monitoring devices, and online doctor consultations are becoming standard among middle- and upper-income urban populations. These changes are reinforcing adherence to therapy regimens and expanding demand for chronic care drugs and personalized treatment plans.

Despite the dominance of urban markets, future growth will also be driven by expanding access to rural India, which houses over 65% of the population. With the increasing penetration of mobile networks, telemedicine platforms, and health insurance coverage in Tier 2 and 3 towns, pharmaceutical firms are actively optimizing rural distribution networks. Customized packaging (smaller SKUs), localized communication, and mobile health campaigns are enabling wider uptake. The digital transformation of supply chains and government-supported infrastructure development is narrowing the urban rural healthcare divide.

Furthermore, the medical devices segment, historically under represented, is emerging as a high-growth vertical. From 54,000 crore in FY18, the industry expanded to 95,000 crore in FY23 and is projected to reach 117,000 crore till now. By FY28, it is expected to grow to 268,000 crore, reflecting a CAGR of 23%. This growth is being driven by improved diagnostic infrastructure, government procurement reform, and increasing domestic manufacturing under the Make in India campaign. India is now the fourth-largest medical device market in Asia, following China, Japan, and South Korea.

Looking ahead, the Indian pharmaceutical sector is poised to benefit from a confluence of powerful trends: a growing population with higher life expectancy, greater incidence of chronic disease, improved affordability, enhanced insurance coverage, and strong state support. However, challenges such as regulatory fragmentation, rising compliance costs, and intensifying competition in the generics space will require companies to innovate in product design, pricing, distribution, and digital integration. If successfully navigated, these changes will not only cement Indias leadership in affordable drug supply but also help establish its competitive edge in high-value and precision therapies globally.

MOREPENS STRATEGY ACTIVE PHARMACEUTICAL INGREDIENDTS (API)

The companys robust R&D and manufacturing capabilities have solidified its position as a global leader in the Active Pharmaceutical Ingredient (API) market, particularly for several critical drugs. The company operates USFDA-approved facilities at Masulkhana, Himachal Pradesh, and Baddi, Himachal Pradesh, ensuring adherence to the highest international quality standards.

The company continues to be a world leader in Loratadine production, a testament to its consistent quality and supply chain reliability. Furthermore, the company has achieved a leadership position as one of the largest suppliers of the anti-asthmatic drug, Montelukast Sodium, produced at its USFDA-approved Masulkhana facility. This site also manufactures Desloratadine, another key anti-histaminic drug. The quality and compliance of these facilities were regularly affirmed, with both the Masulkhana and Baddi sites got re-approval from the USFDA in 2022 for various products including Loratadine, Desloratadine, and Fexofenadine. Demonstrating its expanding global reach, the Masulkhana plant had also secured approval from the prestigious PMDA of Japan in 2023.

The Baddi facility plays a crucial role in the companys diverse API portfolio, being a prominent site for the commercial production of several blockbuster drugs and their intermediates. This includes Anti-hypercholeste-rolemic series: Atorvastatin calcium and Rosuvastatin calcium, Anti-histaminic series: Fexofenadine Hydrochloride and Desloratadine & Anti-hypertensive series: Olmesartan.

In addition to these established products, the Baddi facility is at the forefront of producing newer, high-demand APIs, catering to the needs of customers for formulation development and supply to patent-free countries. This includes: Gliptin series (anti-diabetics): Sitagliptin, Saxagliptin, Linagliptin, and Vildagliptin, Gliflozin series (anti-diabetics): Empagliflozin, Ertugliflozin L-pyroglutamic acid, Dapagliflozin, Propanediol, and Amorphous Dapagliflozin, Anti-depressant category: Vortioxetine hydrobromide and Brexpiprazole, Anti-platelet category: Ticagrelor & Anti-ulcerative category: Vonoprazan fumarate.

This extensive and continuously expanding API portfolio, backed by strong regulatory approvals and a focus on quality, reinforces Morepens position as a reliable and innovative partner in the global pharmaceutical industry.

It is worth noting that the company has successful commercialized Vonoprazan and got approval from CDSCO for its commercial production. The company has also developed / commercialized another blockbuster API, Resmetirom for NASH treatment and is in advanced stages to get its formulation approval from the top Indian Regulator CDSCO.

The company has also developed various new products such as Finerenone (for treatment of chronic kidney disease), Sitagliptin Hydrochloride (Anti-diabetic), Cariprazine HCl (Atypical Anti-Psychotic), Bempedoic Acid (Anti-Hypercholesterolemic) & Rupatadine Fumarate (Anti-histaminic). The company has commercialized Resmetirom (For treatment of NASH), & Bempedoic acid (anti-lipemic category) during last year.

The company is in advanced stages of developing some other recently approved new APIs in R&D like Cenobamate (anti-convulsant), Vibegron (for treatment of overactive bladder), Mavacamten (Cardiovascular agent) & Lisdexamphetamine Dimesylate (for treatment of ADHD) etc.

During the year two USDMFs were filed for Ticagrelor & Brexpiprazole. Two CEPs were filed for Rosuvastatin calcium Process 4 & Sitagliptin phosphate process 2. IDL China DMFs were filed for Vonoprazan & Linagliptin. The Dapagliflozin Propanediol DMFs were filed in Europe-Latvia, Lithuania, Estonia, Czech Republic, Slovak republic, Poland, Germany, Spain, France & Italy. The Dapagliflozin Amorphous DMFs were filed in Croatia, Slovenia, Bulgaria, Sweden, Belgium, Bulgaria, Cyprus, Austria, Malta, Hungary, Romania, Luxemburg, Greece, Portugal, Denmark, Estonia to strengthen the regulatory portfolios.

During the year the company was granted a process patent for preparation of UDCA (For treatment of primary biliary cholangitis). The company also filed ten (10) new process patent applications for Novel processes/ New Polymorphs for Bempedoic Acid, Resmetirom, Brexpiprazole, Finerenone & Rosuvastatin Calcium.

The company has filed 363 Drug Master Files (DMF) over the last many years which includes, 29 USDMF, 13 CEP (Europe), 154 EDMF (European Drug Master File) in Europe, 10 China, Import Drug License (IDL) & 156 DMF in rest of world (RoW). Against 29 USDMF filed in the USA, 6 USDMF have been reviewed under the Generic Drug User Fee Act (GDUFA) of the USA. Out of 13, Certification of Suitability (CEP) filings made in Europe, all 13 CEPs have been granted to the company.

The company has a large and growing high value product portfolio led by regulatory approval in place with integrated manufacturing capacities for APIs company manufacturing, 167 processes/polymorph patents are filed till date. A total of 55 (India 39, Foreign 16) patents have been granted to the company till 31st March 2025.

FORMULATIONS AND MEDICAL DEVICES DIAGNOSTICS

The Medical Devices business has shown robust performance, registering a year-on-year growth of 12.24 percent. This indicates a strong recovery and reinforces its prominent position in the domestic market, further bolstered by increasing online visibility that enhances reach and brand recognition.

Customer Trust and Product Contribution:

Customer trust remains high, attributed to the availability of high-quality, affordable products and a robust service network. The Blood Glucose Monitoring and Blood Pressure Monitoring segments are the primary drivers of revenue growth in this segment. While these flagship products are expected to maintain their dominance, the company foresees revenue expansion from other products, including, Thermometers, Stethoscopes, Digital Weighing Scales, Pregnancy Testing Kits and Other home-health devices.

During last 5 years period, Blood Sugar Monitoring Devices recorded a Compound Annual Growth Rate (CAGR) of 21.00 percent, followed by Blood Pressure Monitoring Devices, recorded a CAGR of 9.56 percent and overall Medical Devices Business, recording a CAGR of 18.35 percent.

The widespread adoption and trust in these products are evident from the cumulative sales of 1.95 billion Gluco Strips and the installation of over 14.20 million Gluco Monitors.

Expansion of Manufacturing Capabilities and Infrastructure:

The Company has made substantial progress in enhancing its manufacturing capabilities and operational integration throughout the year, complemented by the introduction of a new digital health initiative.

In-house Screen Printing: The Company initiated in-house screen-printing operations. This is a strategic step in its backward integration efforts, building upon the prior successful implementation of injection moulding and Surface Mount Technology (SMT). This move aims to bolster control over the entire production process.

Infrastructure Development: A new manufacturing block is currently under construction. This expansion is designed to significantly increase capacities for injection moulding, orthopaedics products, and warehousing, thereby catering to growing demand across various business segments and improving overall operational scalability.

Ortho Products Manufacturing: The Company has broadened its product portfolio by commencing the production of orthopaedics products, marking its strategic entry into this promising new therapeutic segment.

Expanded Quality Certification Scope: The Companys ISO certification now encompasses the design, development, and manufacture of Blood Grouping Reagents and Lateral Flow Test Kits for infectious diseases. This expanded scope highlights the Companys unwavering commitment to delivering high-quality diagnostic solutions and opens new avenues for growth within the medical diagnostics sector.

These strategic manufacturing initiatives underscore the Companys long-term vision of establishing integrated, scalable, and high-quality operations to effectively address the evolving healthcare needs on a global scale.

Introduction of Dr. Morepen Sync App:

The Company has launched the Dr. Morepen Sync App, which it describes as a "gift to the nation." Bearing the tagline "Health in Your Hands," this application is designed to empower individuals to take a proactive role in managing their health. It facilitates easy monitoring of vital health metrics, including blood glucose, blood pressure, and weight, thereby encouraging healthier lifestyles.

Formulations Business Performance Overview

The Formulations business, comprising Formulations Manufacturing and Branded Prescription Drug Distribution, reported revenues of 13868.86 lakhs in the current financial year, reflecting a modest growth of 3.90 percent over the previous years revenue of 13347.80 lakhs.

This performance was delivered despite a major strategic realignment, under which the brand-sharing business was transferred to the subsidiary, Dr. Morepen Limited. The move was designed to streamline operations, sharpen business focus, and enhance the long-term agility of the groups pharmaceutical portfolio.

In line with its evolving strategy, the Company is now focusing on expanding its direct customer base, thereby reducing dependence on low-margin third-party manufacturing. This approach is expected to drive better utilization of in-house manufacturing capacities and promote a stronger mix of high-margin trade and institutional sales, laying the groundwork for improved profitability in the coming years.

INSTITUTIONAL, GENERICS AND CONTRACT MANUFACTURING

Institutional Supplies Business Performance

The Institutional Supplies business demonstrated strong performance during the year, recording revenue of 4952.44 lakhs, reflecting a 14.52 percent year-on-year growth. This increase underscores the Companys growing presence and reliability in the institutional healthcare segment.

Generics Business Performance

The Generics business achieved significant revenue growth, with total revenues rising to 12846.25 lakhs in the current financial year, compared to 8564.85 lakhs in the previous year. This represents a substantial growth of 50 percent, driven by the Companys strategic expansion initiatives. The revenue is segmented between the group entities comprising of Dr. Morepen Limited (DML): 6657.56 lakhs and Morepen Rx Limited: 6188.69 lakhs.

This bifurcation of generics revenue reflects the leadership role taken by Dr. Morepen Limited in driving the generics portfolio, as part of a broader strategy to optimize the business structure and enhance future synergies.

The companys past efforts are yielding positive results, with growth observed across all segments.

Moving forward, the company remains committed to the continued growth and expansion of its Diagnostics, Formulations, and OTC (Over the Counter) businesses.

OPPORTUNITIES AHEAD

The Indian healthcare landscape presents several significant opportunities for growth and innovation, driven by demographic shifts, technological advancements, and supportive government policies.

India is experiencing a notable epidemiological shift towards non-communicable diseases such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses. This trend is creating a sustained and expanding demand for chronic therapies, specialty drugs, and preventive healthcare solutions, offering a long-term growth avenue for pharmaceutical companies.

Vast rural areas and Tier 2/3 cities in India remain underserved by formal healthcare systems. Improved last-mile connectivity, the proliferation of mobile health platforms, and increased insurance penetration through initiatives like Ayushman Bharat and private schemes provide a significant opportunity for pharmaceutical firms to expand their distribution networks and introduce affordable product variants tailored for these markets.

Indian pharmaceutical companies are increasingly investing in complex generics, biosimilars, and niche therapeutics. These areas, while demanding higher R&D capabilities, promise better profit margins. Supportive regulatory frameworks and a growing demand for differentiated products are opening new domestic market segments, particularly in high-growth therapeutic areas such as oncology, dermatology, and rare diseases.

Digital health is revolutionizing healthcare delivery. E-pharmacies already command a significant share (15 18%) of urban drug retail and are expanding at a CAGR exceeding 20 percent. The emergence of platforms offering online doctor consultations, remote diagnostics, wearable device integration, and personalized medication plans is improving treatment adherence and establishing new channels for patient access.

Indias medical devices sector is experiencing rapid growth, outpacing traditional pharma. Projected to grow to 268,000 crore by FY28, this expansion is fueled by enhanced diagnostics infrastructure, increasing demand for home health monitoring solutions, and strong domestic manufacturing incentives under the "Make in India" initiative.

Government initiatives, notably the Ayushman Bharat scheme which now covers over 500 million people, are significantly expanding public health insurance penetration. Continuous government investment in primary healthcare centers, digital health records, and affordable diagnostics is strengthening the formal healthcare system, especially in rural areas. This creates a large, accessible patient base for pharmaceutical products and opens avenues for public procurement.

OUTLOOK ON THREATS, RISKS AND CONCERNS

The Indian pharmaceutical industry, while globally competitive and resilient, continues to face structural weaknesses and external threats that may impact its long-term growth and operational stability. A clear understanding of these challenges is essential for informed decision-making and policy formulation.

Key Weaknesses

1. Heavy Dependence on Imported APIs

India remains significantly reliant on imports-particularly from China-for nearly 70 percent of its Active Pharmaceutical Ingredients (APIs). This over dependence exposes the sector to, Supply chain disruptions, Price volatility in raw materials and Geopolitical tensions. While initiatives to enhance domestic API manufacturing are underway, results will take time to materialize.

2. Fragmented Industry Structure & Quality Inconsistencies

The sector is characterized by a highly fragmented domestic landscape, comprising thousands of small and mid-sized enterprises. This leads to variable compliance standards, inconsistent product quality and challenges in scaling and securing international regulatory approvals. The lack of standardized quality management systems continues to erode confidence in regulatory oversight.

3. Limited R&D Investment & Innovation Gap

Despite being a global generics powerhouse, India invests relatively modestly in R&D as a percentage of revenue. Key concerns include Overreliance on generics and incremental innovations and underdeveloped pipeline for novel drugs, biologics, and complex therapies. This limits long-term growth potential in high-margin, innovation-led segments.

4. Margin Pressures from Price Sensitivity

The domestic markets price-sensitive nature, combined with drug price controls by NPPA, results in Narrow profitability windows and Pressure to drive high-volume sales or shift to premium/differentiated offerings. However, such shifts demand considerable upfront investment in branding, innovation, and distribution.

Major Threats

1. Complex Regulatory Environment & Global Scrutiny

Indian pharma exports face rigorous oversight from agencies such as the USFDA and EMA. Risks include Import bans, Plant shutdowns and Reputational damage. Domestically, inconsistent enforcement and fragmented drug control mechanisms at the state level add further complexity and compliance costs.

2. Rising Competition from Domestic and Global Players

Both multinational corporations and local competitors are increasing their footprint in Indias growing market, resulting in Margin erosion in commoditized categories and Intensified pricing competition. This competitive landscape is accelerating industry consolidation and pressuring smaller players to differentiate or exit.

3. Supply Chain and Logistics Challenges

The sector faces infrastructure bottlenecks, especially in Cold chain logistics, Real-time inventory tracking and Rural and semi-urban last-mile delivery. Additionally, raw material shortages, port delays, and rising transportation costs can impact service reliability and financial performance.

4. Rising Compliance and Operational Costs

Compliance costs are rising due to Stricter global and domestic regulatory norms, Implementation of digital systems like e-labeling and barcode tracking and Enforcement of UCPMP and ethical marketing practices. These developments require investment in skilled compliance personnel, and robust internal controls.

While Indias pharmaceutical industry remains a global leader in generics and vaccines, the path forward demands strategic investment, regulatory harmonization, supply chain strengthening, and R&D innovation. Proactive mitigation of these weaknesses and threats will be critical to maintaining growth momentum and global competitiveness.

FIXED ASSETS

Fixed Assets of the Company are generally well maintained and are in good condition.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company maintains robust internal control systems, appropriately scaled to the size and complexity of its operations. These systems are designed to ensure:

Proper Authorization: All transactions are subject to appropriate approval protocols.

Accurate Recording: Transactions are recorded precisely in accordance with applicable accounting standards and policies.

Timely Reporting: Financial and operational information is reported promptly to support informed decision-making.

Asset Safeguarding: Adequate measures are in place to protect assets from loss, misuse, or unauthorized disposal.

An independent Internal Audit function operates across all critical areas of the Company. The audits are risk-based and systematic, with a primary focus on assessing the effectiveness of internal controls and process adherence. Post-audit reviews are regularly conducted to ensure the timely implementation of audit recommendations, thereby reinforcing a culture of continuous improvement. Any discrepancies or control deficiencies identified during the audit process are addressed promptly and appropriately.

HUMAN RESOURCES

The company places significant emphasis on its human capital, recognizing it as a cornerstone for success and growth. This is achieved through:

Fair and Equal Opportunity: Promoting equitable practices and judiciously rewarding the workforce to maintain a positive work environment.

Employee Engagement: This approach has fostered employee participation in various company activities, contributing to the companys growth trajectory.

The company cultivates pleasant and peaceful interpersonal relationships among its workers, staff, and officers. This is driven by a spirit of collaborative efforts and effective teamwork, resulting in harmonious relationships that lead to improved productivity and a stronger sense of solidarity within the company.

As of 31st March 2025, the groups total manpower strength is 3691, with 2379 employees on permanent payroll. This demonstrates the companys significant contribution to employment and nation-building. The organization is built on a strong foundation of mutual trust, encouraging collective efforts and collaboration across all employee sections. This collaborative environment enables the company to offer quality products at competitive prices, playing a role in Indias growth story.

By steadfastly upholding its core values of fair play, equal opportunity, and value chain enhancement, the Company continues to position itself for sustained growth, long-term success, and responsible corporate leadership.

KEY FINANCIAL RATIOS

Key financial parameters as on 31st March 2025 on the basis of Standalone Financials for the year ending 31st March 2025 & 31st March 2024 respectively are as follows;

Particulars	FY 2025	FY 2024
Debtors Turnover (No. of days)	71	67
Inventory Turnover	3.85	4.40
Current Ratio	2.51	2.39
Debt Equity Ratio	0.07	0.03
Operating Profit Margin	9.87%	10.52%
Net Profit Margin	6.47%	7.16%
Net Capital Turnover Ratio	1.33	1.74
Return on Capital Employed	11.49%	16.46%
Return on Investment	5.94%	8.67%

CAUTIONARY STATEMENT

The company emphasizes the importance of acknowledging that market data and information presented in its reports are derived from various sources, both published and unpublished. The company explicitly states that it cannot guarantee the authenticity of such information. Therefore, users are advised to exercise prudence and consider this limitation when using the data for decision-making.

The management of the company retains the right to reassess any analytical statements and implement necessary actions to maximize shareholder value while simultaneously fulfilling its social and corporate obligations.

Furthermore, the Management Discussions and Analysis Report may contain forward-looking statements. These statements pertain to the companys objectives, strategies, estimates, expectations, predictions, future plans, and projections, and are made in good faith. However, it is crucial to understand that actual results may diverge from the anticipated future performance and outlook presented in the report due to various influencing factors.

Readers are strongly advised to exercise caution and consider the inherent uncertainties when interpreting and acting upon these forward-looking statements. Factors such as market conditions, regulatory changes, economic shifts, and other unforeseen events can impact the companys actual results. Consequently, continuous reassessment of the situation and strategic adjustments are deemed necessary.

	For and on behalf of Board of Directors
	Sushil Suri
Place: Gurugram, Haryana	(Chairman & Managing Director)
Date: 6th August 2025	DIN: 00012028